Interaction of Human Tumor Cells with Human Platelets and the Coagulation System

Hamid Al-Mondhiry; Virginia McGarvey; Kim Leitzel

doi:10.1055/s-0038-1665296

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1983; 50(03): 726-730
DOI: 10.1055/s-0038-1665296

Original Article

Schattauer GmbH Stuttgart

Interaction of Human Tumor Cells with Human Platelets and the Coagulation System

Hamid Al-Mondhiry

The Divisions of Hematology and Oncology, Department of Medicine, the Pennsylvania State University, College of Medicine, the M. S. Hershey Medical Center Hershey, Pennsylvania, U.S.A.

,

Virginia McGarvey

The Divisions of Hematology and Oncology, Department of Medicine, the Pennsylvania State University, College of Medicine, the M. S. Hershey Medical Center Hershey, Pennsylvania, U.S.A.

,

Kim Leitzel

The Divisions of Hematology and Oncology, Department of Medicine, the Pennsylvania State University, College of Medicine, the M. S. Hershey Medical Center Hershey, Pennsylvania, U.S.A.

› Author Affiliations

Abstract

PDF Download

Summary

This paper reports studies on the interaction between human platelets, the plasma coagulation system, and two human tumor cell lines grown in tissue culture: Melanoma and breast adenocarcinoma. The interaction was monitored through the use of ¹²⁵I- labelled fibrinogen, which measures both thrombin activity generated by cell-plasma interaction and fibrin/fibrinogen binding to platelets and tumor cells. Each tumor cell line activates both the platelets and the coagulation system simultaneously resulting in the generation of thrombin or thrombin-like activity. The melanoma cells activate the coagulation system through “the extrinsic pathway” with a tissue factor-like effect on factor VII, but the breast tumor seems to activate factor X directly. Both tumor cell lines activate platelets to “make available” a platelet- derived procoagulant material necessary for the conversion of prothrombin to thrombin. The tumor-derived procoagulant activity and the platelet aggregating potential of cells do not seem to be inter-related, and they are not specific to malignant cells.

Keywords

Factor VIII - Age - Haemophilia - Carriers

PDF (346 kb)

References

References
1 Gralnick HR. Cancer cell procoagulant activity. In: Donati MB, Davidson JF, Garattini S. (eds) Malignancy and the hemostatic system. Raven Press; New York: 1981. p 57
2 Gouault-Heilmann M, Chardon E, Sultan C, Josso F. The procoagulant factor of leukemic promyelocytes. Demonstration of immunologic cross reactivity with human brain tissue factor Br J Haematol 1975; 30: 151-158
3 Sakuragawa N, Takahaski K, Hoshiyama M, Jimbo C, Ashizawa K, Matusuoka M, Ohnishi Y. The extract from tissue of gastric cancer as procoagulant in disseminated intravascular coagulation syndrome. Thromb Res 1977; 10: 457-463
4 Pineo GF, Brain MC, Gallus AS, Hirsh J, Halton MW C, Regoeczi E. Tumors, mucous production and hypercoagulability. Ann NY Acad Sci 1974; 230: 262-270
5 Gasic GJ, Gasic TM, Galanti N, Johnson T, Murphy S. Platelet- tumor cell interaction in miceThe role of platelets in the spread of malignant disease. Int J Cancer 1973; 11: 704-718
6 Hilgard P. The role of platelets in experimental metastases. Br J Cancer 1973; 28: 429-435
7 Gasic GJ, Gasic TB. Plasma membrane vesicles as mediators of interactions between tumor cells and components of the hemostatic and immune system. In: Jamieson GA. (ed) Interaction of platelets and tumor cells.. Alan R. Liss; New York: 1982. p 429
8 Pearlstein E, Saik PL, Yogeeswaran G, Karpatkin S. Correlation between spontaneous metastatic potential, platelet aggregating activity of cell surface extracts and cell surface sialyation in 10 metastatic variant derivatives of a rat renal sarcoma cell line. Proc Natl Acad Sci USA 1980; 77: 4336-4339
9 Pearlstein E, Cooper LB, Karpatkin S. Extraction and characterization of a platelet aggregating material from SV40-transformed mouse 3T3 fibroblasts. J Lab Clin Med 1979; 93: 322-344
10 Karpatkin S, Pearlstein E. Role of platelets in tumor metastasis. Ann Intern Med 1981; 95: 636-641
11 Jones DS, Wallace AC, Fraser EE. Sequence of events in experimental metastases of Walker 256 Tumor: Light, immuno- fluorescent and electron microscopic observations. J Natl Cancer Inst 1971; 46: 493-504
12 Warren BA, Vales O. The adhesion of thromboplastic tumor emboli to vessel walls in vivo. Br J Exp Pathol 1972; 53: 301-313
13 Warren BA. The ultrastructure of platelet pseudopodia and the adhesion of homologous platelets to tumor cells. Br J Exp Pathol 1970; 51: 570-580
14 Warren BA. Tumor metastasis and thrombosis. In: Thrombosis: Pathogenesis and clinical trials. Deutsch E, Lechner K, Brinkhous KM, Hinnom S. (eds) Thrombos Diathes Hemorrh 1974. Suppl 59 140-156
15 Thornes RD. Fibrin and Cancer. Br J Med 1972; 1: 110-111
16 Lipton A, Kepner N, Rogers C, Witkoski E, Leitzel K. Microgenic factor for transformed cells from human platelets. In: Jamieson GA. (ed) Interaction of platelets and tumor cells. Alan R. Liss; New York: 1982. p 233
17 Gasic GJ, Gasic TB, Murphy S. Antimetastatic effect of aspirin. Lancet 1972; 2: 932-933
18 Gasic GJ, Koch PA G, Hsu B, Gasic TB, Niewiaroswski S. Thrombogenic activity of mouse and human tumors: Effect of platelets, coagulation and fibrinolysis. Z Krebs 1976; 86: 263-271
19 Donati MB, Rotillio D, Delaini F, Giavazzi R, Montavani A, Poggi A. Animal model for the study of platelet-tumor cell interactions. In: Jamieson GA. (ed) Interaction of platelets and tumor cells.. Alan R. Liss; New York: 1982. p 159
20 Jamieson GA, Bastida E, Ordinas A. Mechanism of platelet aggregation by human tumor cell lines. Ibid p 405
21 Mohammed SF, Chuang HY K, Szakacs J, Mason RG. Isolation and partial purification of an activity from human pulmonary epidermoid carcinoma cells in culture that clots heparinized plasma. Ibid p 415
22 Zacharaski LR, Handerson W, Rickies FR, Forman WB, Cornell CJ, Fortier RJ, Harrower HW, Johnson RO. Rationale and experimental design for the VA cooperative study of anticoagulation (Warfarin) in the treatment of cancer. Cancer 1979; 44: 732-741
23 Tangen O, Berman HJ. Gel filtration of blood platelets: a methodological report. Adv Exp Med Biol 1972; 34: 235-243
24 Margurie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979; 254: 5357-5363
25 Kazal LA, Amsel S, Miller OP, Tocantis M. The preparation and some properties of fibrinogen precipitated from human plasma by glycine. Proc Soc Exp Biol Med 1963; 113: 989-994
26 Bowie EJ W, Thompson JH, Didisheim P, Owen Jr CA. Mayo clinic laboratory manual of hemostasis. Appendix I W B Saunders; Philadelphia: 1971. p l61
27 Greenwood FC, Hunter WM, Glover JS. The preparation of ¹³¹I-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 89: 114-123
28 Weber K, Osborn M. The reliability of molecular weight determination by deodecyl sulphate polyacrylamide gel electrophoresis. J Biol Chem 1969; 244: 4406-4412
29 Born GV R, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195
30 Horowitz HI, Papayoanou MF. Release of nonsedimentable platelet factor 3 during coagulation. J Lab Clin Med 1967; 69: 1003-1012
31 Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13: 269-288
32 Holme R, Oftebro R, Hovig T. In vitro interaction between cultured cells and human blood platelets. Thromb Haemostas 1978; 40: 89-102
33 Hudig D, Bajaj P. Tissue factor-like activity in human monocytic tumor cell line U937. Thromb Res 1982; 27: 321-332
34 Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: A factor X activating procoagulant from malignant tissue. Thromb Res 1975; 6: 127-137
35 Marguerie GA, Edgington TS, Plow EF. Interaction of fibrinogen with its platelet receptor as a part of a multistep reaction in ADP- induced platelet aggregation. J Biol Chem 1980; 255: 154-161